![NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter](https://pbs.twimg.com/media/DJbom06UEAAQejo.jpg)
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
![Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial - Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b316d514-43f8-43ee-b998-0cbc54128a98/gr1_lrg.jpg)
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -
![Supplemental Materials for Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019 - European Journal of Cancer Supplemental Materials for Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019 - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/cf2ca322-bf68-4aee-9e50-42f54cf7cb4c/fx1_lrg.jpg)
Supplemental Materials for Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019 - European Journal of Cancer
![Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study - ScienceDirect Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804918313959-gr1.jpg)
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study - ScienceDirect
![Figure 5 | Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma Figure 5 | Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma](https://media.springernature.com/full/springer-static/image/art%3A10.1007%2Fs41669-018-0080-5/MediaObjects/41669_2018_80_Fig5_HTML.gif)
Figure 5 | Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
![CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma](https://dailynews.ascopubs.org/do/10.1200/ADN.21.200765/full/dn21_itj_advancedmelanoma_fig_thumbnail.png)
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma
![SciELO - Brasil - Treatment of advanced melanoma - A changing landscape Treatment of advanced melanoma - A changing landscape SciELO - Brasil - Treatment of advanced melanoma - A changing landscape Treatment of advanced melanoma - A changing landscape](https://minio.scielo.br/documentstore/1806-9282/4LH988cHYNSgxBPmP7znMwG/5120c2a43d233dc44210c5d2af68f7afd8880a38.jpg)
SciELO - Brasil - Treatment of advanced melanoma - A changing landscape Treatment of advanced melanoma - A changing landscape
![Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs41669-018-0112-1/MediaObjects/41669_2018_112_Fig2_HTML.png)
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink
![Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial - Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1c1d46c3-5cce-4707-a74a-3c3b160780ac/gr2_lrg.jpg)
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -
![Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma | SCF - Skin Cancer Foundation Provider Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma | SCF - Skin Cancer Foundation Provider](https://provider.skincancer.org/wp-content/uploads/Figure-1-chart.jpg)
Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma | SCF - Skin Cancer Foundation Provider
![Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma - AIM at Melanoma Foundation Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma - AIM at Melanoma Foundation](https://www.aimatmelanoma.org/wp-content/uploads/Blogging-Tips-LinkedIn-Post-Header-25.png)
Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma - AIM at Melanoma Foundation
![Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs41669-018-0080-5/MediaObjects/41669_2018_80_Fig3_HTML.gif)
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
![First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - Journal of Thoracic Oncology First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/843ac863-9a1b-474b-a52e-4569cc79b63d/gr1_lrg.jpg)
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - Journal of Thoracic Oncology
![PDF] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | Semantic Scholar PDF] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/05d8ec52e94baed4fc4663945cff5b66471673c8/4-Figure3-1.png)
PDF] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | Semantic Scholar
![Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a51eabe5-5fcc-41e9-a8d2-131e135f4d7a/gr3.jpg)